CJC-1295 No DAC & Ipamorelin

Ipamorelin / CJC-1295 (No DAC) Overview

The combination of Ipamorelin and CJC-1295 represents one of the most effective pairings in peptide science for the stimulation of endogenous growth hormone (GH) production. By utilizing two distinct pathways of action, this blend achieves a synergistic effect that exceeds the capabilities of either peptide used in isolation.

Ipamorelin is a highly selective agonist of the ghrelin/growth hormone secretagogue receptor. It is widely recognized for its ability to trigger GH release without significantly impacting cortisol, prolactin, or aldosterone levels. Scientific investigation has demonstrated its capacity to enhance skeletal integrity, accelerate muscle tissue repair, and optimize gastrointestinal motility.

CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). It operates by activating GHRH receptors in the pituitary gland. Unlike other secretagogues that may cause unnatural "spikes," CJC-1295 preserves the natural pulsatile pattern of GH release while increasing the amplitude of those pulses. When combined, Ipamorelin elevates the baseline GH concentration while CJC-1295 amplifies the peaks, resulting in a superior metabolic profile and enhanced tissue regeneration.

Product Structure

The molecular composition of these compounds is engineered for high receptor affinity and stability. Below are the plain-text molecular formulas and structural designations for each component:

• Ipamorelin Molecular Formula: C38H49N9O5
• CJC-1295 Molecular Formula: C152H252N44O42
• Structure Solution: 2-amino-N-[1-[[1-[[1-[[6-amino-1-oxo-1-(propylamino)hexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-naphthalen-2-ylpropan-2-yl]amino]-1-oxo-3-(1H-imidazol-5-yl)propan-2-yl]-2-methylpropanamide (Ipamorelin) and Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Ile-Ser-Arg-NH2 (CJC-1295).

Research and Mechanism of Action

The dual-action mechanism of this combination targets the growth hormone pathway through separate but complementary receptors. Research conducted in animal models suggests that this approach yields amplified results in lean tissue composition and skeletal health without a proportional increase in adverse reactions.

Feature

Ipamorelin Mechanism

CJC-1295 Mechanism

Primary Target

Ghrelin/Growth Hormone Secretagogue Receptor

Growth Hormone Releasing Hormone (GHRH) Receptor

GH Pattern

Elevates baseline GH concentrations

Enhances pulsatile peaks and frequency

Secondary Effects

Improves gastric motility and insulin secretion

Enhances insulin sensitivity and lean mass

Selectivity

High (Minimal effect on Cortisol/Prolactin)

High (Specific to GHRH receptors)

The synergy between these two compounds allows for a more natural elevation of growth hormone. Ipamorelin acts as the trigger, mimicking the action of ghrelin and suppressing somatostatin, while CJC-1295 acts as the driver, ensuring the pituitary gland responds with maximum efficiency to the GHRH signal.

Storage and Handling

For maximum stability and shelf life, this lyophilized peptide blend should be stored in a controlled environment:

• Long-term storage: Lyophilized powder should be kept at -20 degrees Celsius.
• Short-term storage: Product may be refrigerated at 2 to 8 degrees Celsius for up to 24 months in its powder form.
• Post-reconstitution: Once the solution is prepared, it must be kept refrigerated and should ideally be used within a 30-day window to ensure maximum potency. Avoid exposure to direct light or high temperatures.

About The Author

The preceding scientific literature underwent research, editing, and compilation by Dr. E. Logan, M.D. Dr. E. Logan earned a medical doctorate from Case Western Reserve University School of Medicine and possesses a Bachelor of Science degree in molecular biology.

Scientific Journal Author

Dr. Dominique Bridon earned a Master of Science in Chemical Engineering and Polymer Sciences from Ecole Nationale Superieure de Chimie and completed his PhD in Organic Chemistry at the University of Paris XI, ICSN, Orsay, France under the mentorship of Nobel Laureate Sir Derek H. R. Barton. His research focused on developing CJC-1295 as an extended-duration GRF analog. He has held leadership roles at Ipsen, Conjuchem, Redcell, and Abbott Laboratories.

Dr. Dominique Bridon is cited here as a prominent researcher in CJC-1295 development. This reference does not constitute an endorsement or recommendation by this scientist for purchasing, selling, or using this product. No relationship, explicit or implicit, exists between Peptide Sciences and this doctor.

Resources

1 K. Raun et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]

2 N. B. Andersen, K. Malmlof, P. B. Johansen, T. T. Andreassen, G. Ortoft, and H. Oxlund, "The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats," Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]123

3 J. Svensson et al., "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats," J. En4docrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed5]6

4 E. Ad7eghate and A. S. Ponery, "Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats," Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]

5 D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients," Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]

6 B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, "Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus," J. Exp. Pharmacol., vol. 4, pp. 149–165, Oct. 2012. [PubMed]

7 M. Alba et al., "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse," Am. J. Physiol. Endocrinol. Metab., vol. 291, no. 6, pp. E1290-1294, Dec. 2006. [PubMed]

8 M. Ionescu and L. A. Frohman, "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog," J. Clin. Endocrinol. Metab., vol. 91, no. 12, pp. 4792–4797, Dec. 2006. [PubMed]

9 M. C. Van Hout and E. Hearne, "Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions," Subst. Use Misuse, vol. 51, no. 1, pp. 73–84, Jan. 2016. [PubMed]

10 Jette, Lucie and Leger, Roger and Thibaudeau, Karen and Benquet, Corinne and Robitaille, Martin and Pellerin, Isabelle and Paradis, Veronique and Wyk, Pieter and Pham, Khan and Bridon, Dominique. (2005). hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog. [Research Gate]